VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update
by Mitch Edgeman · The Markets DailyVivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 91,217 shares, an increase of 512.8% from the March 15th total of 14,885 shares. Based on an average daily volume of 134,350 shares, the short-interest ratio is presently 0.7 days. Currently, 3.6% of the shares of the company are sold short.
VivoSim Labs Price Performance
Shares of NASDAQ:VIVS traded down $0.08 during trading on Friday, hitting $1.45. 22,532 shares of the stock traded hands, compared to its average volume of 114,494. The company has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $2.18. VivoSim Labs has a 52-week low of $1.25 and a 52-week high of $5.30.
VivoSim Labs (NASDAQ:VIVS – Get Free Report) last posted its earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on VIVS
Institutional Investors Weigh In On VivoSim Labs
A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent SEC filing. Institutional investors own 8.23% of the company’s stock.
About VivoSim Labs
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.